Response to: Medical journals and editorial quality control by Erviti et al
- PMID: 31420974
- PMCID: PMC6816055
- DOI: 10.1002/ehf2.12492
Response to: Medical journals and editorial quality control by Erviti et al
Comment on
-
Sacubitril-valsartan in heart failure and multimorbidity patients.ESC Heart Fail. 2018 Oct;5(5):956-959. doi: 10.1002/ehf2.12338. Epub 2018 Jul 24. ESC Heart Fail. 2018. PMID: 30039930 Free PMC article.
-
Medical journals and editorial quality control.ESC Heart Fail. 2019 Oct;6(5):1096. doi: 10.1002/ehf2.12461. Epub 2019 Aug 17. ESC Heart Fail. 2019. PMID: 31420966 Free PMC article. No abstract available.
References
-
- Moliner‐Abós C, Rivas‐Lasarte M, Pamies Besora J et al. Sacubitril/valsartan in real‐life practice: experience in patients with advanced heart failure and systematic review. Cardiovasc Drugs Ther. 2019;33:307–314. - PubMed
-
- Docherty KF, McMurray JJV. Angiotensin receptor‐neprilysin inhibitors: a new paradigm in heart failure with reduced ejection fraction. Int J Cardiol. 2019; 281: 179–185. - PubMed
-
- Gori M, D'Elia E, Senni M. Sacubitril/valsartan therapeutic strategy in HFpEF: clinical insights and perspectives. Int J Cardiol. 2019; 281: 158–165. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
